Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?
2020; BioMed Central; Volume: 18; Issue: 1 Linguagem: Inglês
10.1186/s12959-020-00228-9
ISSN1477-9560
AutoresLorine Giffard-Quillon, H. Desmurs‐Clavel, C. Grangé, Yohann Jourdy, Yesim Dargaud,
Tópico(s)Blood Coagulation and Thrombosis Mechanisms
ResumoRivaroxaban has the most available data to support the use of prothrombin complex concentrates (PCC) as a reversal agent. However, PCC might increase the incidence of thrombotic events by shifting the haemostatic balance towards hypercoagulability. We assessed the in vitro efficacy and safety of three 4-factor PCCs for reversing rivaroxaban anticoagulant effect. Our in vitro finding indicates that 4-factor PCCs at the dose of 25 U.kg- 1 may be sufficient to reverse rivaroxaban anticoagulant effect.
Referência(s)